PA
ENTA icon

PharVision Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

PharVision Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,846
Closed -$429K – 773
2025
Q3 		$429K Buy
+35,846
New +$286K 0.24% 54

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PharVision Advisers's ENTA Position: Q4 2025 in Review

PharVision Advisers sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 35,846 shares — an estimated $429K sold.

PharVision Advisers first reported a position in ENTA in Q3 2025 and held it in 1 quarter. The position peaked at $429K in Q3 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • PharVision Advisers reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 35,846 Enanta Pharmaceuticals shares in Q4 2025, an estimated $429K.
  • PharVision Advisers first reported a position in Enanta Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Enanta Pharmaceuticals position peaked at $429K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.